FGF23 and chronic kidney disease: Moreover, Chue et al. identified in their study, among CKD patients treated with sevelamer, a subgroup with a decrease of FGF23, which was however not accompanied with a change in arterial stiffness, left ventricular mass or cardiac function [133].